
Investors & Media
Investors & Media
- Overview
- News Releases
- Events & Presentations
- Stock Information
- Corporate Governance
- Financial Information
- Investor Resources
Stockholder Tools
News Releases
News Releases
December 13, 2022
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
December 8, 2022
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
November 22, 2022
MeiraGTx to Participate in Upcoming Investor Conferences
November 10, 2022
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.
October 4, 2022
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress
October 1, 2022
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)
September 16, 2022
MeiraGTx’s Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government
September 8, 2022
MeiraGTx to Participate in Upcoming Investor Conferences
August 11, 2022
MeiraGTx Reports Second Quarter 2022 Financial and Operational Results
August 3, 2022
MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities
Displaying 1 - 10 of 17
Investors & Media
- Overview
- News Releases
- Events & Presentations
- Stock Information
- Corporate Governance
- Financial Information
- Investor Resources